DiagnoCure provides update on operations


    Ticker Symbol: CUR

    QUEBEC CITY, April 1 /CNW Telbec/ - DiagnoCure Inc. today provided an
update on its Previstage(TM) GCC Colorectal Cancer Staging Test and its PCA3
test for prostate cancer. "We have recently reached some key milestones, which
represent a great start for 2008 and beyond", said John Schafer, President and
CEO of DiagnoCure.

    Preparing for the launch of Previstage(TM) GCC

    As announced earlier this year, DiagnoCure intends to launch the
Previstage(TM) GCC Colorectal Cancer Staging Test this summer, through its own
reference laboratory which is located in West Chester, PA. "Development of the
test has now been completed in the Company's R&D facilities in Quebec City,
and the test has been transferred to DiagnoCure Oncology Laboratories in West
Chester", stated Mr. Schafer. DiagnoCure's team in the U.S. now includes
7 dedicated employees working on the validation and performance of the test;
they are also setting up the quality and compliance procedures in order to
meet the necessary regulatory requirements before the launch.
    DiagnoCure has also signed a contract with Premier Source Reimbursement
Solutions of South San Francisco, CA, a leading provider of reimbursement
services for pharmaceutical and diagnostic companies. The services provided by
Premier Source will be key to DiagnoCure's efforts to accelerate acceptance of
the Previstage(TM) GCC test.
    At the end of May, DiagnoCure will be exhibiting the Previstage(TM) GCC
Colorectal Cancer Staging Test and DiagnoCure Oncology Laboratories at the
American Society of Clinical Oncology's (ASCO) annual meeting in Chicago. The
conference represents for DiagnoCure a unique opportunity to enhance the
recognition of Previstage(TM) GCC testing by oncologists and other key health
professionals.
    The Previstage(TM) GCC test will identify the presence of occult
metastases, which have been missed by traditional microscopic methods in the
lymph nodes surrounding the colorectal tumor. Occult metastases are known to
be a key indicator of the risk of cancer recurrence. Previstage(TM) GCC could
therefore help physicians make more informed decisions in the treatment of
their colorectal cancer patients.

    Update on PCA3 - Pursuing discussions with Gen-Probe

    Last week, DiagnoCure and Gen-Probe, the Company's PCA3 development and
commercialization partner, participated in the 23rd Annual European
Association of Urology (EAU) Congress that was held in Milan, Italy. Two
posters specifically on the use of the PCA3 test for prostate cancer were
presented, one of which provided more data supporting the clinical value of
PCA3. Also, in related symposiums by Dr. Michael Marberger of Vienna, Austria,
and by Dr. Jack Schalken, from Nijmegen, The Netherlands, the superior value
of PCA3 over free PSA was described.
    These presentations were attended by several hundred clinicians and
represent a significant advance in the communication of PCA3 data to the
European clinical community. The EAU audience is comprised of urologists and
other healthcare specialists throughout Europe and beyond. PCA3 is a highly
specific marker that can help predict the outcome of a prostate biopsy with
much greater accuracy than current PSA testing. DiagnoCure owns worldwide
rights to PCA3 and licensed the diagnostic rights to Gen-Probe in 2003.
    Based on the agreement signed in 2003 and amended in 2006, Gen-Probe had
until March 31, 2008 to submit their version of a PCA3 test to the Food and
Drug Administration (FDA). Since Gen-Probe decided to hold off on a PCA3
pivotal clinical study in the United States until they can reformulate the
assay to run on their investigational Panther platform, the timeline has not
been met and accordingly, Gen-Probe could lose market exclusivity. DiagnoCure
is pursuing constructive discussions with Gen-Probe, and is committed to
achieving an outcome that will best benefit its shareholders, patients and
their physicians.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ: GPRO) for the development and
commercialization of a second- generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.



For further information: Investors: J.F. Bureau, CFA, Sr. Vice President
and CFO, DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com;
Media: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates, (514) 347-6111,
jp.trudel@videotron.ca